A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication (LAURITE 2)

未提供0 个研究点目标入组 138 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 138

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized

入排标准

年龄范围: 18age old over 至 80age old under（—）
性别: All

入选标准

•Participant should be male or female, >=18 years of age at the time of signing the informed consent.
•Moderate or severe (Grade 2 or 3) GL at MF at baseline, as assessed by the ILA using a validated 4-point photographic scale.
•Moderate or severe (Grade 2 or 3) GL at MF at baseline, as assessed by the SSA using a 4-point categorical scale.
•Are 'dissatisfied' or 'very dissatisfied' with their GLs at baseline, as assessed by the SLS score.
•For female participants: Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
•Participant has both the time and ability to complete the study and comply with study instructions.
•Does not reside in an institution by administrative or court order.
•Is not a sponsor employee or clinical research unit personnel directly affiliated with the study or is not an immediate family member. Immediate family is defined as a spouse, parent, child or sibling whether biological or legally adopted.

排除标准

•An active infection or other skin problems in the upper face including the GL area (e.g. acute acne lesions or ulcers).
•A history of eyelid blepharoplasty or brow lift or any other upper facial surgery within the past 5 years.
•A history of facial nerve palsy.
•Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring or thick sebaceous skin.
•Closed-angle glaucoma or a predisposition to it (for Japan only).
•Any known medical condition that may put the participant at increased risk with regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.).
•Presence of any scars, piercings, or tattoos (including microblading of the eyebrows) in or around the treatment area that have occurred within 6 months prior to baseline, or which in the investigator's opinion, could interfere with evaluations.
•Administration of any BoNT (other than the study intervention) into any site of the body and for any indication from 9 months prior to the first study visit until the end of the study.
•Treatment with IPN10200 in any prior study.
•Use of medications that affect neuromuscular transmission (such as curare-like nondepolarising agents, lincosamides, polymyxins, anticholinesterases) within the past 30 days prior to baseline is prohibited or a longer washout period of at least five half lives might be required, as deemed appropriate by the investigator for long-acting medications.
•Use of aminoglycoside antibiotics within the past 30 days prior to baseline are prohibited. Note: Topical use apart from the area of injection would be acceptable.
•Use of systemic retinoids within the past 30 days prior to baseline and planned use during the study. Note: Topical retinoids are allowed other than in the areas that will be injected (upper facial area) at the discretion of the investigator.
•Any prior treatment with permanent fillers, lifting threads, autologous fat or permanent procedures in the upper face including the GL area.
•Administration of any nonpermanent injectables (such as hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid or polymethyl-methacrylate) for soft tissue augmentation therapy in the GL region within 12 months prior to baseline.
•Any prior facial treatment or aesthetic procedures to the upper face including photorejuveBlanktion, vascular or pigment laser or microneedling within the 3 months prior to baseline.
•Any prior facial treatment or aesthetic procedures to the upper face involving skin resurfacing (including dermabrasion, laser, or whatever the interventioBlankl technique used) or chemical peel within the past 12 months prior to baseline.
•Any planned cosmetic surgery or aesthetic procedures to the upper face during the study and/or any procedures to other parts of the face which in the investigator's opinion, could interfere with evaluations during the study.
•Any past surgery in the upper facial line area including GL.
•Planned use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention. Therapy considered necessary for the participant's welfare may be given at the discretion of the investigator. Note: If the permissibility of a specific medication/treatment is in question, the medical monitor will be contacted.
•Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented termiBlankl half-life of the respective drug or its metabolites or if the half-life is unknown within 30 days prior to the start of the study (prior to baseline) and during the conduct of the study.
•Known positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus or a diagnosis of acquired immunodeficiency syndrome.
•Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study.
•An inability to substantially lessen GL as determined by the investigator.
•Known allergy or hypersensitivity to BoNT or any excipients of IPN
•A history of chronic or recreatioBlankl drug abuse as assessed by the investigator.
•Any uncontrolled systemic disease or other significant medical condition which would be harmful for the participant to be entered into the study or continue participation.

研究者

发起方

未提供

相似试验

招募中

1 期

A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

2024-519010-31-00Fondazione Melanoma Onlus80

招募中

2/3 期

A Study to check Immunogenicity and Safety of A Trivalent Nanoparticle Influenza Vaccine and Covid-Influenza Combination Vaccine in Adults

CTRI/2025/10/095731Serum Institute of India Private Limited (SIIPL)2,400

招募中

2/3 期

This is a comparative Phase II/ III study of bevacizumab with ranibizumab in an eye condition called Wet AMD. A total of 202 subjects are planned to be enrolled in this study, the primary outcome is to evaluate the efficacy of RLS bevacizumab in improving vision.

CTRI/2025/05/087515Reliance Life Sciences Pvt Ltd202

进行中（未招募）

3 期

Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients.

CTRI/2024/02/062974Samsung Bioepis Co Ltd616

招募中

2 期

A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy

CTRI/2025/05/087905Novo Nordisk200